Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) gapped down prior to trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $47.39, but opened at $42.75. Kiniksa Pharmaceuticals International shares last traded at $45.3940, with a volume of 187,028 shares trading hands.

The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.20). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. During the same quarter in the prior year, the business posted ($0.12) earnings per share. The company’s revenue was up 65.0% compared to the same quarter last year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KNSA. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.71.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry D. Quart sold 2,690 shares of the stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director owned 12,546 shares of the company’s stock, valued at $564,570. The trade was a 17.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 123,823 shares of company stock worth $5,244,967 over the last 90 days. 53.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently modified their holdings of KNSA. Savant Capital LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $398,000. GSA Capital Partners LLP grew its position in Kiniksa Pharmaceuticals International by 281.9% during the third quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock valued at $3,028,000 after acquiring an additional 57,566 shares during the period. Aberdeen Group plc acquired a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $6,163,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth $1,480,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Kiniksa Pharmaceuticals International in the second quarter valued at about $1,648,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Performance

The firm has a market capitalization of $3.45 billion, a PE ratio of 100.84 and a beta of 0.06. The firm has a fifty day moving average of $42.83 and a 200 day moving average of $39.56.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.